PPARA and congenital secretory chloride diarrhea 1: In addition, a phase II clinical trial on lanifibranor, a pan-PPAR agonist, for the treatment of experimental advanced chronic liver disease [135], showed that lanifibranor improved portal hypertension and hepatic fibrosis, indicating that it may have the potential to be used for CLD treatment.